Childhood onset psoriasis has a profound impact on the development and quality of life of pediatric patients. Consequently, validated patient-reported outcome measures (PROMs) for pediatric psoriasis are vital to patient care. We sought to critically appraise the literature on the measurement properties of PROMs used in the pediatric psoriasis population. We performed a 2-stage systematic literature synthesis in MEDLINE (1950–2017) and EMBASE (1947–2017) to identify PROMs and studies evaluating their measurement properties. Analysis of studies followed the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) methodology to inform a best evidence synthesis. From 1,128 articles, we identified 29 PROMs. Subsequently, we identified 8 studies evaluating the measurement properties of 7 instruments. Among these instruments, the Simplified Psoriasis Index (SPI) achieved a positive rating for criterion validity, the Dutch version of the Children’s Dermatology Life Quality Index (CDLQI) achieved a positive rating for hypothesis testing, and the Swedish version of the CDLQI achieved a negative rating for hypothesis testing. All other assessed measurement properties received indeterminate or unknown ratings due to flaws in study design. PROMs are paramount to the management of pediatric psoriasis. This synthesis emphasizes the critical need for additional studies to further describe the measurement properties of PROMs used in pediatric psoriasis and identify validated, standardized measures for use in clinical practice and research.

Keywords:
Outcome measures, Pediatric dermatology, Psoriasis, Pediatric psoriasis, Juvenile psoriasis, Patient-reported outcome measures, Patient-reported outcomes, Measurement properties, Psychometrics
1.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM: Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377–385.
2.
Fotiadou C, Lazaridou E, Ioannides D: Management of psoriasis in adolescence. Adolesc Health Med Ther 2014; 5: 25–34.
3.
Garshick MK, Kimball AB: Psoriasis and the life cycle of persistent life effects. Dermatol Clin 2015; 33: 25–39.
4.
Fox FE, Rumsey N, Morris M: “Ur skin is the thing that everyone sees and you cant change it”: exploring the appearance-related concerns of young people with psoriasis. Dev Neurorehabil 2007; 10: 133–141.
5.
Kimball AB, Wu EQ, Guérin A, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM: Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol 2012; 67: 651–657.
6.
Mokkink LB, Terwee CB, Patrick DL, Alonso J, Statford PW, Knol DL, Bouter LM, de Vet HC: The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res 2010; 19: 539–549.
7.
Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, de Vet HC: The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 2010; 63: 737–745.
8.
Callis Duffin K, Merola JF, Christensen R, Latella J, Garg A, Gottlieb AB, Armstrong AW: Identifying a core domain set to assess psoriasis in clinical trials: a combined Delphi consensus survey from the International Dermatology Outcome Measures Initiative. JAMA Dermatol 2018, Epub ahead of print.
9.
Callis Duffin K, Gottlieb AB, Merola JF, Latella J, Garg A, Armstrong AW: Defining outcome measures for psoriasis: the IDEOM report from the GRAPPA 2016 annual meeting. J Rheumatol 2017; 44: 701–702.
10.
Elman SA, Merola JF, Armstrong AW, Duffin KC, Latella J, Garg A, Gottlieb AB: The International Dermatology Outcome Measures (IDEOM) initiative: a review and update. J Drugs Dermatol 2017; 16: 119–124.
11.
Gottlieb AB, Levin AA, Armstrong AW, Abernethy A, Duffin KC, Bhushan R, Garg A, Merola JF, Maccarone M, Christensen R: The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. J Am Acad Dermatol 2015; 72: 345–348.
12.
Merola JF, Armstrong AW, Saraiya A, Latella J, Garg A, Callis Duffin K, Gottlieb AB: International Dermatology Outcome Measures Initiative as applied to psoriatic disease outcomes: an update. J Rheumatol 2016; 43: 959–960.
13.
Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC: Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res 2012; 21: 651–657.
14.
Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC: Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007; 60: 34–42.
15.
Terwee CB: Protocol for Systematic Reviews of Measurement Properties. Amsterdam, COSMIN, 2011.
16.
Furlan AD, Pennick V, Bombardier C, van Tulder M: 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976) 2009; 34: 1929–1941.
17.
Oostveen AM, Jong EM, Evers AW, Donders AR, van de Kerkhof PC, Seyger MM: Reliability, responsiveness and validity of Scalpdex in children with scalp psoriasis: the Dutch study. Acta Derm Venereol 2014; 94: 198–202.
18.
Van Geel MJ, Otero ME, de Jong EM, van de Kerkhof PC, Seyger MM: Validation of the Simplified Psoriasis Index in Dutch children and adolescents with plaque psoriasis. Br J Dermatol 2017; 176: 771–776.
19.
Salek MS, Jung S, Brincat-Ruffini LA, MacFarlane L, Lewis-Jones MS, Basra MK, Finlay AY: Clinical experience and psychometric properties of the Children’s Dermatology Life Quality Index (CDLQI), 1995–2012. Br J Dermatol 2013; 169: 734–59.
20.
Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NA: Quality of life impact of childhood skin conditions measured using the Children’s Dermatology Life Quality Index (CDLQI): a meta-analysis. Br J Dermatol 2016; 174: 853–861.
21.
Oostveen AM, de Jager ME, van de Kerkhof PC, Donders AR, de Jong EM, Seyger MM: The influence of treatments in daily clinical practice on the Children’s Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry. Br J Dermatol 2012; 167: 145–149.
22.
De Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM: A cross-sectional study using the Children’s Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores. Br J Dermatol 2010; 163: 1099–1101.
23.
Van Geel MJ, Maatkamp M, Oostveen AM, de Jong EM, Finlay AY, van de Kerkhof PC, Seyger MM: Comparison of the Dermatology Life Quality Index and the Children’s Dermatology Life Quality Index in assessment of quality of life in patients with psoriasis aged 16–17 years. Br J Dermatol 2016; 174: 152–157.
24.
Gånemo A, Wahlgren CF, Svensson Å: Quality of life and clinical features in Swedish children with psoriasis. Pediatr Dermatol 2011; 28: 375–379.
25.
Langley RG, Paller AS, Hebert AA, Creamer K, Weng HH, Jahreis A, Globe D, Patel V, Orlow SJ: Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol 2011; 64: 64–70.
26.
Varni JW, Seid M, Rode CA: The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 1999; 37: 126–139.
27.
Gonzalez J, Cunningham K, Perlmutter J, Gottlieb A: Systematic review of health-related quality of life in adolescents with psoriasis. Dermatology 2016; 232: 541–549.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.